Sökning: id:"swepub:oai:prod.swepub.kib.ki.se:137567904" >
Menopausal hormone ...
Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway
-
Botteri, E (författare)
-
Stoer, NC (författare)
-
Sakshaug, S (författare)
-
visa fler...
-
Graff-Iversen, S (författare)
-
Vangen, S (författare)
-
Hofvind, S (författare)
-
de Lange, T (författare)
-
Bagnardi, V (författare)
-
Ursin, G (författare)
-
- Weiderpass, E (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2017-11-15
- 2017
- Engelska.
-
Ingår i: BMJ open. - : BMJ. - 2044-6055. ; 7:11, s. e017639-
- Relaterad länk:
-
https://bmjopen.bmj....
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- With the present study, we aimed to investigate the association between menopausal hormone therapy (HT) and risk of colorectal cancer (CRC).SettingCohort study based on the linkage of Norwegian population-based registries.ParticipantsWe selected 466822 Norwegian women, aged 55–79, alive and residing in Norway as of 1 January 2004, and we followed them from 2004 to 2008. Each woman contributed person-years at risk as non-user, current user and/or past HT user.Outcome measuresThe outcome of interest was adenocarcinoma of the colorectal tract, overall, by anatomic site and stage at diagnosis. Incidence rate ratios (RRs) with 95% CIs were estimated by Poisson regression and were used to evaluate the association between HT and CRC incidence.ResultsDuring the median follow-up of 4.8 years, 138 655 (30%) women received HT and 3799 (0.8%) incident CRCs occurred. Current, but not past, use of HT was associated with a lower risk of CRC (RR 0.88; 95% CI 0.80 to 0.98). RRs for localised, regionally advanced and metastatic CRC were 1.13 (95% CI 0.91 to 1.41), 0.81 (95% CI 0.70 to 0.94) and 0.79 (95% CI 0.62 to 1.00), respectively. RRs for current use of oestrogen therapy (ET) were 0.91 (95% CI 0.80 to 1.04) while RR for current use of combined oestrogen–progestin therapy (EPT) was 0.85 (95% CI 0.70 to 1.03), as compared with no use of HT. The same figures for ET and EPT in oral formulations were 0.83 (95% CI 0.68 to 1.03) and 0.86 (95% CI 0.71 to 1.05), respectively.ConclusionsIn our nationwide cohort study, HT use lowered the risk of CRC, specifically the most advanced CRC.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
BMJ open
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Botteri, E
-
Stoer, NC
-
Sakshaug, S
-
Graff-Iversen, S
-
Vangen, S
-
Hofvind, S
-
visa fler...
-
de Lange, T
-
Bagnardi, V
-
Ursin, G
-
Weiderpass, E
-
visa färre...
- Artiklar i publikationen
-
BMJ open
- Av lärosätet
-
Karolinska Institutet